Weekly injections of semaglutide, the active ingredient in Ozempic and Wegovy, led to significant reductions in body weight and knee osteoarthritis-related pain, according to a phase 3 study by Novo Nordisk.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
